235 related articles for article (PubMed ID: 11694699)
21. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
Vignati L; Anderson JH; Iversen PW
Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
[TBL] [Abstract][Full Text] [Related]
22. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
Roach P; Trautmann M; Arora V; Sun B; Anderson JH
Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
[TBL] [Abstract][Full Text] [Related]
23. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
24. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
Wilde MI; McTavish D
Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
[TBL] [Abstract][Full Text] [Related]
25. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
[TBL] [Abstract][Full Text] [Related]
26. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight.
Mohn A; Matyka KA; Harris DA; Ross KM; Edge JA; Dunger DB
Diabetes Care; 1999 Jan; 22(1):27-32. PubMed ID: 10333899
[TBL] [Abstract][Full Text] [Related]
27. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
[TBL] [Abstract][Full Text] [Related]
29. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
Anderson JH; Brunelle RL; Keohane P; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
Arch Intern Med; 1997 Jun; 157(11):1249-55. PubMed ID: 9183237
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
Ross SA; Zinman B; Campos RV; Strack T;
Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
[TBL] [Abstract][Full Text] [Related]
31. Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50.
Gao Y; Li G; Li Y; Guo X; Yuan G; Gong Q; Yan L; Zheng Y; Zhang J
Int J Clin Pract; 2008 Sep; 62(9):1344-51. PubMed ID: 18657196
[TBL] [Abstract][Full Text] [Related]
32. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.
Raskin P; Holcombe JH; Tamborlane WV; Malone JI; Strowig S; Ahern JA; Lavent F
J Diabetes Complications; 2001; 15(6):295-300. PubMed ID: 11711322
[TBL] [Abstract][Full Text] [Related]
33. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
[TBL] [Abstract][Full Text] [Related]
34. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.
Pfützner A; Küstner E; Forst T; Schulze-Schleppinghoff B; Trautmann ME; Haslbeck M; Schatz H; Beyer J
Exp Clin Endocrinol Diabetes; 1996; 104(1):25-30. PubMed ID: 8750567
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Humalog injections before an afternoon meal and their acceptance by children and adolescents with type 1 diabetes.
Martin D; Licha-Müntz G; Grasset E; Grenèche MO; Nouet D; François L; Legrand C; Polak M; Augendre-Ferrante B; Tubiana-Rufi N; Robert JJ
Diabet Med; 2002 Dec; 19(12):1026-31. PubMed ID: 12647845
[TBL] [Abstract][Full Text] [Related]
36. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
Rassam AG; Zeise TM; Burge MR; Schade DS
Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
[TBL] [Abstract][Full Text] [Related]
37. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen?
Heller SR; Amiel SA; Evans ML; Kong MF; Macdonald IA; Peacey SR
Diabetes Obes Metab; 2002 Mar; 4(2):106-12. PubMed ID: 11940107
[TBL] [Abstract][Full Text] [Related]
38. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin.
Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM
Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428
[TBL] [Abstract][Full Text] [Related]
39. Optimal time of administration of insulin lispro. Importance of meal composition.
Strachan MW; Frier BM
Diabetes Care; 1998 Jan; 21(1):26-31. PubMed ID: 9538966
[TBL] [Abstract][Full Text] [Related]
40. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.
Melki V; Renard E; Lassmann-Vague V; Boivin S; Guerci B; Hanaire-Broutin H; Bringer J; Belicar P; Jeandidier N; Meyer L; Blin P; Augendre-Ferrante B; Tauber JP
Diabetes Care; 1998 Jun; 21(6):977-82. PubMed ID: 9614617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
